AkzoNobel and MMG Show Regulators Are Testing Remedies in Practice

Merger remedies are no longer just negotiated on paper; regulators are now testing whether they can actually function in the market.

Updated

What is this trend?

Regulators are moving from accepting merger remedies on paper to testing whether divestitures and supply commitments can work in practice, raising the bar for clearance.

  • Full divestitures now need real operating separation, not just asset transfers.
  • Regulators are stress-testing buyers, transition services, and trustee oversight before clearing deals.
  • Supply guarantees can be held open until authorities see they will hold up in market.
  • Remedy planning now has to start at deal design, not after signing.
  • Execution risk is shifting from legal drafting to operational credibility.

What’s the latest?

On 6 November 2026, the European Commission cleared AkzoNobel’s merger with Axalta only after forcing a full divestiture of AkzoNobel’s EEA vehicle-refinish coatings business, including manufacturing

How it developed

  1. AI-Embedded Diligence, Regulatory Deal Risk, and JV-First Structuring Redefine Corp Dev
  2. Clearance Risk Moves Upstream, AI Shifts Execution, and JV Control Gets Rewritten
  3. Governed AI, control-stack deals, earlier merger review, and carve-out separation programs
  4. AI deal-room controls, litigation-aware clearance, and governance-heavy AI add-ons reshape dealmaking

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by seniority.

Related trends

Stay ahead in Corporate Development (M&A)

Get the weekly Corporate Development (M&A) brief in your inbox — the developments, what they mean by seniority, and what to do next.